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Abstract
Background: Whole brain radiation therapy (WBRT) is widely used for the treatment of brain metastases. Cognitive
decline and alopecia are recognized adverse effects of WBRT. Recently hippocampus sparing whole brain radiation
therapy (HS-WBRT) has been shown to reduce the incidence of memory loss. In this study, we found that multi-field
intensity modulated radiation therapy (IMRT), with strict constraints to the brain parenchyma and to the hippocampus,
reduces follicular scalp dose and prevents alopecia.
Methods: Suitable patients befitting the inclusion criteria of the RTOG 0933 trial received Hippocampus sparing whole
brain radiation. On follow up, they were noticed to have full scalp hair preservation. 5 mm thickness of follicle bearing
scalp in the radiation field was outlined in the planning CT scans. Conventional opposed lateral WBRT radiation fields
were applied to these patient-specific image sets and planned with the same nominal dose of 30 Gy in 10 fractions.
The mean and maximum dose to follicle bearing skin and Dose Volume Histogram (DVH) data were analyzed for
conventional and HS-WBRT. Paired t-test was used to compare the means.
Results: All six patients had fully preserved scalp hair and remained clinically cognitively intact 1–3 months
after HS-WBRT. Compared to conventional WBRT, in addition to the intended sparing of the Hippocampus,
HS-WBRT delivered significantly lower mean dose (22.42 cGy vs. 16.33 cGy, p < 0.0001), V24 (9 cc vs. 44 cc, p < 0.0000)
and V30 (9 cc vs. 0.096 cc, p = 0.0106) to follicle hair bearing scalp and prevented alopecia. There were no recurrences
in the Hippocampus area.
Conclusions: HS-WBRT, with an 11-field set up as described, while attempting to conserve hippocampus radiation and
maintain radiation dose to brain inadvertently spares follicle-bearing scalp and prevents alopecia.
Keywords: Hippocampus sparing, Alopecia, IMRT
Background
Cognitive impairment after WBRT is a significant problem
with 50–90 % of patients showing measurable decline on
testing and 10–15 % showing progressive clinical cognitive
decline, with significant effect on quality of life [1–4].
While medical therapies (donapezil and memantine) have
been used to prevent and treat cognitive decline associ-
ated with WBRT, they can be costly and may result in
adverse effects or non-compliance [5, 6]. HS-WBRT has
shown to be safe, feasible and promising in reducing
cognitive decline [7–9].
HS-WBRT, usually performed with intensity modula-
tion (IMRT), utilizes iterative planning to restrict dose
to hippocampus while maintaining dose to the rest of
the brain parenchyma as anatomically defined. The strict
dose-volume parameters have been studied and pre-
scribed in the recently completed and published RTOG
trail, which showed significantly less decline in cognitive
function with HS-WBRT [7].
Radiation induced alopecia is well-known and signifi-
cant side effect of conventional WBRT [10, 11]. While
the significance of radiation-induced alopecia has been
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recognized, and attempts been made to mitigate or
prevent it, it has been accepted as an unavoidable conse-
quence. Dose response to alopecia [12] and other inter-
ventions to mitigate alopecia have been described. We
report dose volume analysis to scalp, comparing conven-
tional and HS-WBRT. This was in response to noticing
hair preservation in all our patients treated with an
11-field HS-WBRT.
Materials and Methods
Patients with brain metastasis who fulfill the eligibility cri-
teria for RTOG 0933 were included in this study. No pa-
tients had preexisting alopecia, including systemic
chemotherapy induced alopecia, and had a full comple-
ment of scalp hair. The first 6 consecutive patients who
received HS-WBRT who were noticed to have full preser-
vation of scalp hair on follow up were analyzed. All
patients had diagnostic brain MRI with contrast. A
thermoplastic mask immobilization was used with CT
simulation. CT-MRI fusion was used for target volume de-
lineation. A simplified and reproducible in-house 11-field
IMRT plan, with 9 coplanar (0° couch angle) of 6MV pho-
tons and 2 coronal (90° couch angle) beams of 10MV pho-
tons were used. This was preferred to the recommended
beam arrangements in the RTOG trial, which involved
multiple gantry and couch angles. The suggested field
setup in the RTOG trial and the setup used in this study
are compared in Fig. 1. All dosimetric guidelines and pa-
rameters used in the RTOG 0933 trial were used and met.
The dose volume constraints to the hippocampus, the
hippocampus avoidance zone, brain parenchyma and the
organs at risk – including the lenses, optic nerves and
optic chiasm, were met for all patients. A representative
treatment plan is shown in Fig. 2.
5 mm hair follicle bearing scalp was auto contoured in
all CT simulation image data sets retrospectively (Fig. 3).
Conventional opposed lateral fields with MLC (Multi
Leaf Collimator) blocks were applied to all image sets as
would be used to treat with conventional WBRT with
6MV photons. The dose volume parameters to the
follicle-bearing scalp for both plans were calculated.
All patients were followed one month after and three
monthly thereafter until progression or death, with clin-
ical examination including mini mental state and brain
MRI. As these patients were treated outside protocol, a
complete neuro-cognitive assessment battery of tests
was not performed.
Paired t-test to compare the means was utilized using
STATAR software (Statacorp LP, College Station, Texas
77845, USA).
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Fig. 1 Field setup used in RTOG 0933 and in current study
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The retrospective review was IRB approved – hence
the protocol for the research project has been approved
by a suitably constituted Ethics Committee of the in-
stitution within which the work was undertaken and
that it conforms to the provisions of the Declaration
of Helsinki, and the study does not violate the pol-
icies and/or procedures established by the Journal.
Results
Clinical outcomes
At the time of their one-month and last follow up all
patients had full scalp hair preservation (Fig. 4), by their
own subjective reporting and on clinical examination.
All patients experience fatigue, but no other neurological
toxicity. One patient died of a stroke, presumed unre-
lated, one month after HS-WBRT. Two patients had
recurrent brain metastasis. No patients failed in the
Hippocampus avoidance zone or in the skull base. All
six patients had clinically preserved cognitive function.
Dosimetric outcomes
The mean, maximum, V24 (volume of follicle bearing
scalp receiving 24 Gy) and V30 (volume of follicle bear-
ing scalp receiving 30 Gy) for each patient are shown in
Table 1. Compared to HS-WBRT, conventional WBRT
delivered significantly higher mean dose to follicle bearing
scalp (16.33 cGy vs. 22.42 cGy, p < 0.0001). The volume of
radiated hair bearing scalp receiving 24 Gy – V24 (9 cc vs.
44 ml, p < 0.0000) and V30 (0.096 ml vs. 9 ml), p = 0.0106)
were also significantly higher. Dose Volume Histograms
(DVHs) illustrating differences in the volume of hair fol-
licle bearing scalp-receiving threshold dose for alopecia
(V24) and prescribed dose (V30) are shown in Fig. 5.
Discusssion
Radiation to scalp with sufficient doses can lead to alope-
cia [12]. Conventional WBRT does not seek to limit dose
to scalp and causes alopecia. Hippocampus sparing WBRT
while attempting to rigidly enforce dose compliance to
brain and normal structures including the hippocampus
Fig. 2 Graphic Plan of HS-WBRT (top 3 panels) and Conventional WBRT (bottom 3 panels)
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and the hippocampus avoidance zone, can spare hair fol-
licle bearing scalp of significant radiation and prevents
alopecia.
WBRT has long been the standard of care for brain me-
tastasis. It significantly improves survival when indicated
for prophylaxis [13, 14] and therapy [15]. Neurocognitive
decline after WBRT is a recognized complication [16–18].
Attempts have been made to mitigate this with adjuvant
medication modulating neurotransmission [5, 6]. Medica-
tion to prevent cognitive decline after WBRT can be
costly, have problems with side effects and compliance
and the benefits are modest. Randomized trials have also
shown that addition of WBRT to local therapy (Stereotac-
tic radiosurgery or resection) may not improve survival
but significantly decreases the likelihood of distant brain
failure [3, 4, 19, 20]. Hence there is a trend to omit WBRT
altogether to avoid cognitive decline. However recurrent
brain metastasis, which could have been prevented, can
also be detrimental neurologically and may cause cogni-
tive decline [21, 22]. With the realization of sensitive
structures of the brain involved in neuro-cognitive pro-
cessing in the Hippocampus area [9], and the likelihood of
harboring metastasis or recurrence of metastasis in this
zone being rare [8, 23], HS-WBRT has emerged as a viable
treatment option to preserve the benefits of WBRT and
yet decrease the probability of neuro-cognitive decline.
Indeed a recently completed co-operative group trial con-
firmed the feasibility and the neuro-cognitive protective
function of HS-WBRT [7]. This strategy avoids the add-
itional cost, side effects and frequent non-compliance
associated with the medications for preventing and treat-
ing neuro-cognitive decline. Encouraged by this our group
initiated HS-WBRT for patients meeting the eligibility in
this trial.
HS-WBRT has been shown to be feasible by multiple
groups, with or without integrated boost using linear
accelerator-based multi-field IMRT [24], Volumetric Mod-
ulated Arc Therapy (VMAT) [25–27] or Tomotherapy
techniques [28]. Specific IMRT techniques have been
Fig. 3 Auotcontour of Hair Follicle bearing scalp. Lower Right panel is NOT a treatment field but a template for the extent of temporal hair
bearing scalp
Fig. 4 Hair preservation 1 and 3 months after HS-WBRT
Mahadevan et al. Radiation Oncology  (2015) 10:245 Page 4 of 7
recommended and used in the RTOG 0933 trial [24].
However the 9-Field IMRT technique recommended in
this trial with multiple individual couch angles ranging
from 6–354° and multiple individual gantry angles from
9–319° were found, by us, to be unwieldy, cumbersome,
time consuming and fraught with potential collision and
setup errors. After experimenting with multiple simple
beam arrangements we found it feasible to reproducibly
achieve all DVH constraints as prescribed, with two fixed
standard couch position in 0° and 90° and fixed coplanar
gantry angles, thereby eliminating collision risk and sig-
nificantly simplifying and shortening of patients’ setup.
Tolerance dose to scalp has been reported for perman-
ent alopecia after definitive radiation therapy for brain tu-
mors [12, 29]. Hair loss, at least temporarily, occurs in
most patients receiving WBRT with conventional fraction-
ation [11]. This has been consistently shown to translate
to poor quality of life within their reduced life expectancy
in these patients [10, 14, 30, 31]. Attempts have been made
to use topical nitroxides [32, 33], prostagladin E [34],
botulinum toxin [35] and vasoconstrictors [36] to decrease
the incidence and severity of alopecia after radiation ther-
apy. However the no clinical benefit was found. Scalp
dose-limiting WBRT techniques have been described pre-
viously. Roberge et al. measured surface scalp doses with
TLD and calculated doses at 5 mm thickness and reported
decrease in mean doses of 53 % and 38 % respectively
[37]. Mancini et al. similarly demonstrated decrease scalp
dose after VMAT- IMRT [38]. In a more detailed analysis
De Puysseleyr et al., using preliminary cadaveric data and
in a prospective study using VMAT IMRT for scalp
sparing, showed 37 % reduction to the median dose
to the hair follicle volume [39]. However, this unfortu-
nately did not translate into clinical benefit with poor
QOL and Alopecia scores. Differences in technique
(VMAT vs. Tomotherapy vs. Multi Field IMRT), energy,
beam arrangement, objectives (hippocampus sparing vs.
scalp sparing), contouring of hair bearing scalp, DVH
Table 1 Hair follicle bearing scalp dose in cGy
Patient Mean Max V24 V30
LATS HS-WBRT LATS HS-WBRT LATS Hs-WBRT LATS HS-WBRT
1 2364.8 1189.7 3586.7 2997.8 51.94 0.26 23.71 0
2 2247.7 1715.6 3375 3795.5 45.59 11.5 6.84 0.21
3 2282.1 1623.9 3383.2 3107.8 46.2 6.47 6.77 0.01
4 2171.2 1827 3333.7 3280.6 40.16 16.69 3.94 0.21
5 2313.2 1646.7 3418 3352.1 50.59 10.56 11.62 0.08
6 2076 1797.4 3205.8 3238.7 30.33 13.38 1.17 0.07
Mean 2242.5 1633.383 3383.733 3295.417 44.135 9.81a 9.008333 0.096667a
LATS Opposed lateral fields, HS-WBRT Hippocampus sparing – whole brain radiation therapy, Max Maximum scalp dose, V24 Volume of hair bearing skin receiving
24 Gyin cc, V30 Volume of hair bearing skin receiving 30 Gyin cc.
aStatistically significant
Fig. 5 DVH (Dose Volume Histogram) showing scalp dose with conventional WBRT (dashed line) and HS-WBRT (solid line)
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constraints and DVH parameters could account for the
apparent differences in these outcomes.
Conclusion
While other IMRT set-ups have independently shown
hippocampus sparing or scalp sparing, in our study we
demonstrate dual benefit of Hippocampus sparing and,
unexpectedly, scalp sparing effects of an 11-field IMRT
technique. This is likely to even more enhance the quality
of life in suitable patients receiving WBRT for brain
metastasis, and will be worthy of evaluating prospectively.
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